ReviewCNS drugs2006
Tailoring nicotine replacement therapy: rationale and potential approaches.
Review in CNS drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A process evaluation of 'We Can Quit': a community-based smoking cessation intervention targeting women from areas of socio-disadvantage in Ireland.BMC public health · 2022Trial
- Adherence to and consumption of nicotine replacement therapy and the relationship with abstinence within a smoking cessation trial in primary care.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013Trial
- Association of PolymorphismInternational journal of environmental research and public health · 2022Article
- Temporal Trends of Psychosociobehavioral Factors Underlying Tobacco Use: A Semi-Automated Exploratory Analysis of Peer-to-Peer Communication in a Health-Related Online Community.Studies in health technology and informatics · 2017Article
- Nicotine reinforcement in never-smokers.Psychopharmacology · 2015Article
- Quitting experiences and preferences for a future quit attempt: a study among inpatient smokers.BMJ open · 2015Article
- Nicotine replacement therapy use among smokers and ex-smokers: associated attitudes and beliefs: a qualitative study.BMC public health · 2014Article
- Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence.Experimental and clinical psychopharmacology · 2009Article
- Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Article
- Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2009Article
- Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century.International journal of environmental research and public health · 2009Review
- Update on pharmacologic and nonpharmacologic therapies for smoking cessation.Canadian family physician Medecin de famille canadien · 2008Review
- Genetics of nicotine dependence and pharmacotherapy.Biochemical pharmacology · 2008Review
- Varenicline: A review of the literature and place in therapy.Pharmacy practice · 2007Article
- Review
- Tobacco use and cessation for cancer survivors: an overview for clinicians.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nicotine replacement therapy (NRT) is an effective treatment for smoking cessation, but as with all such pharmacotherapies, the majority of smokers who use NRT products do not stop smoking or remain abstinent long term. Treatment outcome is affected by a range of individual-specific factors, as well as the pharmacokinetic profile of each NRT formulation. This has led to speculation that abstinence rates could be improved if NRT treatments were individually tailored to best match each individual's needs and preferences. There are also populations for whom special product and dosage considerations are warranted to maximise treatment safety.This paper reviews the rationale for NRT treatment, standard dose recommendations and recommendations for how to best match NRT treatment to the specific needs of individual smokers. We also review emerging evidence that genetic profiling may one day be a useful consideration for tailoring NRT treatment.
Indexed as
Identifiers
16599646What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.